Who
John Vavricka
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Atea Pharmaceuticals.
In numbers
- Trades disclosed
- 26
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $45K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Nov 2020
- Last trade
- 31 Jan 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —42,083 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $49K11,570 at $4.24 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,333 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,333 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,750 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —119,520 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,750 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —119,520 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —42,083 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $49K11,570 at $4.24 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,333 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,750 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —132,800 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —33,333 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —8,750 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $35K11,517 at $3.06 | filing |
| 1 Feb 2024filed 2 Feb 2024 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $45K11,819 at $3.84 | filing |
| 31 Jan 2024filed 2 Feb 2024 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,334 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —132,800 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —33,334 | filing |
News
No headline names them, or the companies they trade most, lately.